These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 16133391)
1. Further investigations of morpholino pretargeting in mice--establishing quantitative relations in tumor. Liu G; He J; Dou S; Gupta S; Rusckowski M; Hnatowich DJ Eur J Nucl Med Mol Imaging; 2005 Sep; 32(9):1115-23. PubMed ID: 16133391 [TBL] [Abstract][Full Text] [Related]
2. Predicting the biodistribution of radiolabeled cMORF effector in MORF-pretargeted mice. Liu G; Dou S; He J; Liu X; Rusckowski M; Hnatowich DJ Eur J Nucl Med Mol Imaging; 2007 Feb; 34(2):237-46. PubMed ID: 17021815 [TBL] [Abstract][Full Text] [Related]
3. Pretargeting in tumored mice with radiolabeled morpholino oligomer showing low kidney uptake. Liu G; He J; Dou S; Gupta S; Vanderheyden JL; Rusckowski M; Hnatowich DJ Eur J Nucl Med Mol Imaging; 2004 Mar; 31(3):417-24. PubMed ID: 14691611 [TBL] [Abstract][Full Text] [Related]
4. Investigations of 99mTc morpholino pretargeting in mice. Liu G; Liu C; Zhang S; He J; Liu N; Gupta S; Rusckowski M; Hnatowich DJ Nucl Med Commun; 2003 Jun; 24(6):697-705. PubMed ID: 12766607 [TBL] [Abstract][Full Text] [Related]
5. Tumor pretargeting in mice using (99m)Tc-labeled morpholino, a DNA analog. Liu G; Mang'era K; Liu N; Gupta S; Rusckowski M; Hnatowich DJ J Nucl Med; 2002 Mar; 43(3):384-91. PubMed ID: 11884499 [TBL] [Abstract][Full Text] [Related]
6. Amplification targeting: a modified pretargeting approach with potential for signal amplification-proof of a concept. He J; Liu G; Gupta S; Zhang Y; Rusckowski M; Hnatowich DJ J Nucl Med; 2004 Jun; 45(6):1087-95. PubMed ID: 15181145 [TBL] [Abstract][Full Text] [Related]
7. Tumor pretargeting in mice using MORF conjugated CC49 antibody and radiolabeled complimentary cMORF effector. Liu G; Dou S; Pretorius PH; Liu X; Chen L; Rusckowski M; Hnatowich DJ Q J Nucl Med Mol Imaging; 2010 Jun; 54(3):333-40. PubMed ID: 20639818 [TBL] [Abstract][Full Text] [Related]
8. An improved method for covalently conjugating morpholino oligomers to antitumor antibodies. He J; Liu G; Dou S; Gupta S; Rusckowski M; Hnatowich D Bioconjug Chem; 2007; 18(3):983-8. PubMed ID: 17385902 [TBL] [Abstract][Full Text] [Related]
9. Affinity enhancement pretargeting: synthesis and testing of a 99mTc-labeled bivalent MORF. He J; Wang Y; Dou S; Liu X; Zhang S; Liu G; Hnatowich D Mol Pharm; 2010 Aug; 7(4):1118-24. PubMed ID: 20507096 [TBL] [Abstract][Full Text] [Related]
10. Pretargeting CWR22 prostate tumor in mice with MORF-B72.3 antibody and radiolabeled cMORF. Liu G; Dou S; Pretorius PH; Liu X; Rusckowski M; Hnatowich DJ Eur J Nucl Med Mol Imaging; 2008 Feb; 35(2):272-80. PubMed ID: 17909792 [TBL] [Abstract][Full Text] [Related]
11. The influence of chain length and base sequence on the pharmacokinetic behavior of 99mTc-morpholinos in mice. Liu G; Zhang S; He J; Liu N; Gupta S; Rusckowski M; Hnatowich DJ Q J Nucl Med; 2002 Sep; 46(3):233-43. PubMed ID: 12134139 [TBL] [Abstract][Full Text] [Related]
12. Synthesis and in vitro characterization of a dendrimer-MORF conjugate for amplification pretargeting. Chen X; Dou S; Liu G; Liu X; Wang Y; Chen L; Rusckowski M; Hnatowich DJ Bioconjug Chem; 2008 Aug; 19(8):1518-25. PubMed ID: 18646837 [TBL] [Abstract][Full Text] [Related]
13. 90Y labeled phosphorodiamidate morpholino oligomer for pretargeting radiotherapy. Liu G; Dou S; Liu Y; Wang Y; Rusckowski M; Hnatowich DJ Bioconjug Chem; 2011 Dec; 22(12):2539-45. PubMed ID: 21985267 [TBL] [Abstract][Full Text] [Related]
14. A preclinical 188Re tumor therapeutic investigation using MORF/cMORF pretargeting and an antiTAG-72 antibody CC49. Liu G; Dou S; Baker S; Akalin A; Cheng D; Chen L; Rusckowski M; Hnatowich DJ Cancer Biol Ther; 2010 Oct; 10(8):767-74. PubMed ID: 21099368 [TBL] [Abstract][Full Text] [Related]
15. Successful radiotherapy of tumor in pretargeted mice by 188Re-radiolabeled phosphorodiamidate morpholino oligomer, a synthetic DNA analogue. Liu G; Dou S; Mardirossian G; He J; Zhang S; Liu X; Rusckowski M; Hnatowich DJ Clin Cancer Res; 2006 Aug; 12(16):4958-64. PubMed ID: 16914585 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics in mice of four oligomer-conjugated polymers for amplification targeting. He J; Liu G; Zhang S; Rusckowski M; Hnatowich DJ Cancer Biother Radiopharm; 2003 Dec; 18(6):941-7. PubMed ID: 14969606 [TBL] [Abstract][Full Text] [Related]
17. A comparison of in vitro and in vivo stability in mice of two morpholino duplexes differing in chain length. He J; Liu G; Zhang S; Vanderheyden JL; Liu N; Liu C; Zhang Y; Gupta S; Rusckowski M; Hnatowich DJ Bioconjug Chem; 2003; 14(5):1018-23. PubMed ID: 13129406 [TBL] [Abstract][Full Text] [Related]
18. Construction of a novel chimera consisting of a chelator-containing Tat peptide conjugated to a morpholino antisense oligomer for technetium-99m labeling and accelerating cellular kinetics. Zhang YM; Tung CH; He J; Liu N; Yanachkov I; Liu G; Rusckowski M; Vanderheyden JL Nucl Med Biol; 2006 Feb; 33(2):263-9. PubMed ID: 16546682 [TBL] [Abstract][Full Text] [Related]
19. Adding a clearing agent to pretargeting does not lower the tumor accumulation of the effector as predicted. Liu G; Dou S; Chen X; Chen L; Liu X; Rusckowski M; Hnatowich DJ Cancer Biother Radiopharm; 2010 Dec; 25(6):757-62. PubMed ID: 21204772 [TBL] [Abstract][Full Text] [Related]
20. Preparation of (111)In-DTPA morpholino oligomer for low abdominal accumulation. Liu G; Dou S; Rusckowski M; Greiner D; Hnatowich D Appl Radiat Isot; 2010 Sep; 68(9):1709-14. PubMed ID: 20359901 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]